These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 32021143

  • 1. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
    Chen R, Zhong N, Wang HY, Zhao L, Mei X, Qin Z, Huang J, Assam PN, Maes A, Siddiqui S, Martin UJ, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
    [Abstract] [Full Text] [Related]

  • 2. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
    [Abstract] [Full Text] [Related]

  • 3. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Martinez FJ, Lipworth BJ, Rabe KF, Collier DJ, Ferguson GT, Sethi S, Feldman GJ, O'Brien G, Jenkins M, Reisner C.
    Respir Res; 2020 May 25; 21(1):128. PubMed ID: 32450869
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C, Pearle J, Kerwin EM, Rose ES, Darken P.
    Int J Chron Obstruct Pulmon Dis; 2018 May 25; 13():1965-1977. PubMed ID: 29950826
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
    Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C.
    Respir Med; 2017 May 25; 126():105-115. PubMed ID: 28427541
    [Abstract] [Full Text] [Related]

  • 6. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA.
    Lipworth BJ, Collier DJ, Gon Y, Zhong N, Nishi K, Chen R, Arora S, Maes A, Siddiqui S, Reisner C, Martin UJ.
    Int J Chron Obstruct Pulmon Dis; 2018 May 25; 13():2969-2984. PubMed ID: 30310273
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
    Ferguson GT, Rodriguez-Roisin R, Reisner C, Maes A, Siddiqui S, Martin UJ.
    Int J Chron Obstruct Pulmon Dis; 2018 May 25; 13():945-953. PubMed ID: 29606861
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Gon Y, Nishi K, Sato K, Maes A, Siddiqui S, Hayashi N, Hirata H, Martin UJ, Reisner C.
    Respir Investig; 2021 Jan 25; 59(1):135-144. PubMed ID: 32917556
    [Abstract] [Full Text] [Related]

  • 9. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C, Fabbri LM, Kerwin EM, Fogarty C, Spangenthal S, Rabe KF, Ferguson GT, Martinez FJ, Donohue JF, Darken P, St Rose E, Orevillo C, Strom S, Fischer T, Golden M, Dwivedi S.
    Respir Res; 2017 Jan 06; 18(1):8. PubMed ID: 28061907
    [Abstract] [Full Text] [Related]

  • 10. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
    Maltais F, Ferguson GT, Feldman GJ, Deslee G, Bourdin A, Fjällbrant H, Siwek-Posłuszna A, Jenkins MA, Martin UJ.
    Adv Ther; 2019 Sep 06; 36(9):2434-2449. PubMed ID: 31267366
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
    Ferguson GT, Reisner C, Pearle J, DePetrillo P, Maes A, Martin UJ.
    Pulm Pharmacol Ther; 2018 Apr 06; 49():67-74. PubMed ID: 29567116
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
    Martinez FJ, Rabe KF, Ferguson GT, Fabbri LM, Rennard S, Feldman GJ, Sethi S, Spangenthal S, Gottschlich GM, Rodriguez-Roisin R, Arora S, Siler TM, Siddiqui S, Darken P, Fischer T, Maes A, Golden M, Orevillo C, Reisner C.
    Chest; 2017 Feb 06; 151(2):340-357. PubMed ID: 27916620
    [Abstract] [Full Text] [Related]

  • 13. Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD.
    De Backer W, De Backer J, Verlinden I, Leemans G, Van Holsbeke C, Mignot B, Jenkins M, Griffis D, Ivanov S, Fitzpatrick J, St Rose E, Martin UJ, Reisner C.
    Ther Adv Respir Dis; 2020 Feb 06; 14():1753466620916990. PubMed ID: 32380894
    [No Abstract] [Full Text] [Related]

  • 14. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
    Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C.
    Respir Med; 2016 Nov 06; 120():16-24. PubMed ID: 27817811
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
    Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C.
    Int J Chron Obstruct Pulmon Dis; 2019 Nov 06; 14():2979-2991. PubMed ID: 31920295
    [Abstract] [Full Text] [Related]

  • 16. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD.
    Siddiqui MK, Shukla P, Jenkins M, Ouwens M, Guranlioglu D, Darken P, Biswas M.
    Ther Adv Respir Dis; 2019 Nov 06; 13():1753466619894502. PubMed ID: 31868101
    [Abstract] [Full Text] [Related]

  • 17. An Open-Label Study Evaluating the Performance of the Dose Indicator in a Metered Dose Inhaler Delivering Glycopyrrolate and Formoterol Fumarate in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease.
    Pudi K, Feldman G, Fakih F, Mack P, Maes A, Siddiqui S, St Rose E, Reisner C.
    J Aerosol Med Pulm Drug Deliv; 2019 Feb 06; 32(1):40-46. PubMed ID: 30335559
    [Abstract] [Full Text] [Related]

  • 18. Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease.
    Fakih F, Spangenthal S, Sigal B, Darken P, Maes A, Siddiqui S, Gillen M, Reisner C, Martin UJ.
    Respir Med; 2018 May 06; 138():74-80. PubMed ID: 29724397
    [Abstract] [Full Text] [Related]

  • 19. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
    Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C.
    Lancet Respir Med; 2018 Oct 06; 6(10):747-758. PubMed ID: 30232048
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects.
    Reisner C, Miller J, DePetrillo P, Maes A, Siddiqui S, Martin UJ.
    Pulm Pharmacol Ther; 2018 Dec 06; 53():33-38. PubMed ID: 30218695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.